NEXAVAR®

Hold Company

BAYER HLTHCARE

Learn More

Dosage and Administration

TABLET;ORAL

Specification

EQ 200MG BASE

Indication

NEXAVAR® is applicable to hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

Use

Instructions for Use

API

SORAFENIB TOSYLATE

API Structure

We Supply

SORAFENIB TOSYLATE

Note:

Facility GMP
ASMF/CEP/USMF

Drug Patent

Patent No	Expiration Date
8877933	2027/12/24
9737488	2028/9/10

API Patent

Patent No	Expiration Date
8877933	2027/12/24

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.